Bojungikki-Tang Improves Response to PD-L1 Immunotherapy by Regulating the Tumor Microenvironment in MC38 Tumor-Bearing Mice

Immune checkpoint blockage targeting PD-L1 has led to breakthroughs in cancer treatment. Although anti-PD-L1-based immunotherapy has been approved as standard therapy in various cancer types, its therapeutic efficacy in most colorectal cancers (CRC) is still limited due to the low response to immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Chun, Jaemoo, Park, Sang-Min, Yi, Jin-Mu, Ha, In Jin, Kang, Han Na, Jeong, Mi-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300825/
https://www.ncbi.nlm.nih.gov/pubmed/35873573
http://dx.doi.org/10.3389/fphar.2022.901563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300825/
https://www.ncbi.nlm.nih.gov/pubmed/35873573
http://dx.doi.org/10.3389/fphar.2022.901563

Ejemplares similares